Werewolf Therapeutics (NASDAQ:HOWL) Stock Breaks Below Fifty Day Moving Average – Should You Sell?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) crossed below its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $0.98 and traded as low as $0.97. Werewolf Therapeutics shares last traded at $0.97, with a volume of 217,807 shares trading hands.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 3rd. Weiss Ratings raised Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. Finally, Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.00.

Werewolf Therapeutics Stock Performance

The firm’s 50 day moving average is $0.98 and its 200-day moving average is $0.70. The stock has a market capitalization of $47.14 million, a price-to-earnings ratio of -1.28 and a beta of 0.55.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of hedge funds have recently made changes to their positions in HOWL. Bank of America Corp DE purchased a new position in shares of Werewolf Therapeutics in the second quarter worth about $112,000. Covestor Ltd acquired a new position in Werewolf Therapeutics in the 3rd quarter valued at about $124,000. Squarepoint Ops LLC acquired a new position in Werewolf Therapeutics in the 2nd quarter valued at about $37,000. BlackRock Inc. acquired a new position in Werewolf Therapeutics in the 2nd quarter valued at about $37,000. Finally, Vontobel Holding Ltd. purchased a new stake in shares of Werewolf Therapeutics in the 3rd quarter valued at approximately $55,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues. Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer.